Aim: Development of a specific polymerase chain reaction (PCR) assay for detection ofthe pre-core, stop codon, mutant of hepatitis B virus (HBV). Methods: PCR primers, specific at the 3'-end for nucleotide 1896 of either the pre-core, stop codon, mutant or wild type HBV, were synthesised using published sequence data. Positive control templates for both types of virus were synthesised by the PCR, incorporating sequences specific for each virus type at the appropriate position. These templates were used to optimise the specificity of the procedure. Formalin fixed, paraffin wax embedded human tissue from acute or fulminant HBV hepatitis from Hong Kong or Oxford was then investigated for presence of mutant or wild type virus. The HBV DNA was amplified from this tissue using a two step procedure, with an initial amplification phase followed by a second diagnostic phase on optimally diluted target DNA.
optimise the specificity of the procedure. Formalin fixed, paraffin wax embedded human tissue from acute or fulminant HBV hepatitis from Hong Kong or Oxford was then investigated for presence of mutant or wild type virus. The HBV DNA was amplified from this tissue using a two step procedure, with an initial amplification phase followed by a second diagnostic phase on optimally diluted target DNA. Results: Specific detection of mutant or wild type HBV was achieved. An important factor in determining specificity was the temperature of annealing, 70°C proving to be highly specific. To overcome the inherent variation of target copy number in clinical samples and to provide an intrinsic positive control, it was important to generate and standardise the amount of target HBV used for the specific PCR has been associated with the viral mutant.' 7 In some of these cases it has been shown that the presumed contact of the patient has the mutant strain as a sole or dominant form, suggesting an initial infection with the mutant as a cause of the fulminant hepatitis, rather than selection from a mixed infection.5 7 In view of the medical importance of this viral mutant rapid detection methods for the mutant will be very useful. We have thus developed a procedure for detecting the mutant virus using a variation of the polymerase chain reaction-allele specific PCR. This procedure depends on the discovery that the allele specificity of a PCR primer is determined predominantly by its 3-end. 8 to a "diagnostic phase" using allele specific PCR. This two-step approach is illustrated in fig 4. As the starting material for the "diagnostic phase" is a PCR product, the system is )2 on essentially analogous to the one we used for the 1)-establishment of allele specificity of the primers.
e
To provide an internal control during the "diagnostic phase" allele specific PCR, we included a third primer COMM-1 in all allele specific amplifications. COMM-1 and 2017 primed the synthesis of a 329 base pair PCR product which acted as a positive control. MUT-A/2017 and NOR-A/2017 would direct amplification from the mutant and wild type viruses, respectively.
As a preliminary investigation using the allele specific PCR assay, we chose three patients with fulminant hepatitis B (two from Hong Kong and one from Oxford) and four patients with acute hepatitis B from Hong Kong. PCR was carried out from paraffin wax embedded liver biopsy specimens, as outlined. Following the "amplification phase", a 329 base pair HBV-PCR product was visible from all seven cases (results not shown). After the "diagnostic phase" only the wild type viral sequence was detected in all seven patients ( fig  5) . The 329 base pair internal positive control was visible in all tracks, thus excluding amplification failure as the reason behind our inability to detect mutant HBV in the three cases of fulminant hepatitis. 
Discussion
Compared with previously described methods for the detection of the pre-core HBV mutant such as sequencing23' 7 and allele specific oligonucleotide (ASO) hybridisation," our method is rapid and completely non-radioactive. The ability of the technique to use paraffin wax embedded tissues as starting material suggests that the method may be used for large scale retrospective analysis of the role of the mutant in a variety of liver diseases.
The use of a two-step approach involving an "amplification phase" followed by a "diagnostic phase" overcomes several difficulties of applying an allele specific PCR assay to formalin fixed, paraffin wax embedded tissues. First, the exact amount of amplifiable nucleic acid present in paraffin wax embedded tissues may vary from case to case and these tissues may amplify with varying efficiencies.'0 "1 Second, the viral titre may also differ from patient to patient. Both of these problems are solved by the two-step approach in which the "amplification phase" is aimed at amplifying the viral 1 2 3 Lo, Lo, Tse, Flenming molecules present in a tissue section to a PCR plateau. This is followed by gel quantification and then a pre-determined amount of the PCR product is then subjected to a "diagnostic phase" which has been calibrated to handle this quantity of product. This two-step strategy should be suitable to any use of allele specific PCR to paraffin wax embedded tissues and thus may have important uses in other diagnostic situations.
In our preliminary series of three cases of fulminant hepatitis B, only the wild type virus was found. While this contradicts the published findings of the role of the mutant virus in a number of Japanese56 and Israeli7 cases of fulminant hepatitis B, our results are similar to the data reported in cases from the USA."5 Taken together, these data suggest a geographical variation in the involvement of precore HBV mutants in fulminant hepatitis B. We are currently undertaking a larger study to establish the generality of these observations. Tlhe rapidity of the allele specific PCR assay should make this goal attainable.
With the accumulation of sequence information on HBV and other viruses, increasing numbers of viral variants will be discovered. Allele specific PCR is an efficient method for the detection of these viral variants.
